Biologics by design
Clague P. Hodgson, Ph.D.
Founder, Chief Executive Officer
Clague Hodgson, NTC’s founder brings 30 years experience in basic and applied genetics research and lab management. Clague previously held faculty positions at Creighton University School of Medicine and The Ohio State University. He was trained at the University of Minnesota (undergraduate and graduate), and at the Mayo Graduate School of Medicine (Ph.D.), with postdoctoral training at Baylor College of Medicine. He has published numerous scientific articles, book chapters, patents, and a book on gene therapy.
Jim Williams, Ph.D.
Chief Scientific Officer,
Vice President for Research and Development
Jim Williams, Ph.D., Vice President, R&D, Chief Scientific Officer –Dr. Williams is a specialist in non-viral expression vector systems and has extensive experience with biologic development. Dr. Williams expertise includes molecular biology, regulatory affairs, quality, molecular genetics, fermentation, and protein expression systems. Dr. Williams joined NTC from Restoragen, where he held a variety of Vice Presidential offices including Regulatory Affairs, Quality and Process Development and Molecular Biology. At Restoragen, Dr. Williams followed the process of drug development from concept through pre-clinical testing and into clinical trials. Dr. Williams has held positions at Ophidian Pharmaceutical heading teams developing recombinant protein production processes and vaccines. He has a Ph.D. in genetics from the University of Alberta, completed postdoctoral training at the University of Wisconsin, and has numerous publications and 31 issued US patents and multiple foreign equivalents. Dr Williams is the inventor of NTC’s vector innovations including the Nanoplasmid™ platform.
Aaron Carnes, B.Sc.Ch.
Vice President of Manufacturing
Aaron Carnes has over 18 years of experience in plasmid DNA production and purification at scales ranging from microgram to multi-gram quantities of plasmid DNA. He led NTC’s process development efforts that resulted in multiple patents, publications, and an upstream plasmid production platform (HyperGRO™) which achieves some of the highest plasmid yields reported in the peer reviewed literature. He has presented on plasmid manufacturing and vector technology at numerous conferences. Aaron has participated in several technology transfers of the HyperGRO™ process to GMP manufacturing facilities. Aaron holds a B.S. in Chemical Engineering from the University of Nebraska.
Deborah Moorad-Watts, M.B.A.
Business Development and Licensing
Deborah Moorad-Watts leads business development and licensing for Nature Technology Corporation. Moorad-Watts has over 10 years’ experience leading both start-ups and fortune 500 companies product commercilaization, business development, and intellectual property strategy. She has led product commercilaization efforts from concept through launch, and managed intellectual property and licensing strategy with pharmaceutical and medical device companies across the world. Her previous accomplishments include the launch and management of an investigational drug for glioblastoma, that was later acquired.
Colleen S. Nygren
Secretary Treasurer and Financial Services
Colleen Nygren, is the Secretary Treasurer, and manages the accounting, finance, banking and corporate administration activities at NTC. She also provides support for human resources management, patent fee payments, leasehold contacts and shareholder communications. Colleen has worked with NTC since 2001 and has a business degree from the University of Nebraska.